Related Experiment Video
Updated: Oct 4, 2025

A Possible Zebrafish Model of Polycystic Kidney Disease: Knockdown of wnt5a Causes Cysts in Zebrafish Kidneys
Published on: December 2, 2014
WIN site inhibition disrupts a subset of WDR5 function
Andrew J Siladi1, Jing Wang2,3, Andrea C Florian1
1Department of Cell and Developmental Biology, Vanderbilt University School of Medicine, 465 21st Avenue South, Nashville, TN, 37232, USA.
WIN site inhibitors only partially disable WDR5, and histone H3 lysine 4 methylation changes do not drive cancer cell responses. This suggests distinct therapeutic applications for WDR5 inhibitors and degraders.
Area of Science:
- Molecular Biology
- Epigenetics
- Cancer Research
Background:
- WDR5 is crucial for assembling histone-modifying complexes and has roles beyond this in chromatin regulation.
- WDR5 is a key pharmacological target in cancer, with drug discovery focusing on inhibiting its WIN site.
- WIN site inhibitors are assumed to broadly disable WDR5 functions and alter histone H3 lysine 4 methylation (H3K4me) to drive cancer cell transcriptional responses.
Purpose of the Study:
- To investigate the assumptions underlying the therapeutic application of WDR5 WIN site inhibitors.
- To compare the effects of WIN site inhibition versus WDR5 degradation on H3K4me and cellular transcription.
- To elucidate the precise mechanisms of action for WDR5-targeting drugs.
Main Methods:
- Comparative analysis of WDR5 WIN site inhibition and WDR5 degradation.
- Assessment of H3K4me levels following WDR5 manipulation.
- Transcriptional profiling of cancer cells treated with WDR5 inhibitors or degraders.
Main Results:
- WIN site inhibition affects only a subset of WDR5 activities.
- H3K4me alterations resulting from WDR5 depletion do not account for observed transcriptional changes.
- WDR5 degradation leads to different outcomes compared to WIN site inhibition.
Conclusions:
- WIN site inhibitors function as selective loss-of-function agents, not broad inhibitors of WDR5.
- H3K4me is not the primary mechanism driving cancer cell transcriptional responses to WDR5 inhibitors.
- WIN site inhibitors and WDR5 degraders possess distinct clinical applications and therapeutic potential.
Related Concept Videos
Canonical Wnt Signaling Pathway
Non-Canonical Wnt Signaling Pathways
Inhibition of Cdk Activity
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
Enzyme Inhibition
Pleiotropy

